Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 46, Issue 5, 2005, Pages 693-701

  Zu, Youli ^a   Steinberg, Seth M ^a   Campo, Elias ^b   Hans, Christine P ^c   Weisenburger, Dennis D ^c   Braziel, Rita M ^d   Delabie, Jan ^e   Gascoyne, Randy D ^f   Muller Hermlink, Konrad ^g   Pittaluga, Stefania ^a   Raffeld, Mark ^a   Chan, Wing C ^c   Jaffe, Elaine S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Diffuse large B cell lymphoma; Immunohistochemistry; Monoclonal antibodies; Prognostic markers; Tissue microarray; Validation

Indexed keywords

BIOLOGICAL MARKER; CD20 ANTIGEN; CD3 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; TRANSCRIPTION FACTOR;

B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; HEMATOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LARGE CELL LYMPHOMA; PATHOLOGIST; PHENOTYPE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCORING SYSTEM; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; VALIDATION PROCESS;

ANALYSIS OF VARIANCE; DATA INTERPRETATION, STATISTICAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS;

EID: 20144366490     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500051844     Document Type: Review

References (37)

1. Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Meth 1987;103:121-129.
2. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
3. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31.
4. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 2001;70:255-264.
5. Tzankov A, Zimpfer A, Lugli A, Krugmann J, Went P, Schraml P, Maurer R, Ascani S, Pileri S, Geley S, Dirnhofer S. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates over-expression of cyclin E1. J Pathol 2003;199:201-207.
6. Skacel M, Skilton B, Pettay JD, Tubbs RR. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol 2002;10:1-6.
7. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80:1943-1949.
8. Griffin MC, Robinson RA, Trask DK. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol 2003;16:1181-1188.
9. Gulmann C, Butler D, Kay E, Grace A, Leader M. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 2003;42:70-76.
10. Leversha MA, Fielding P, Watson S, Gosney Jr, Field JK. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol 2003;200:610-619.
11. Nielsen TO, Hsu FD, O'Connell JX, Gilks CB, Sorensen PH, Linn S, West RB, Liu CL, Botstein D, Brown PO, van de Rijn M. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003;163:1449-1456.
12. Rassidakis GZ, Jones D, Thomaides A, Sen F, Lai R, Cabanillas F, McDonnell TJ, Medeiros LJ. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol 2002;118:328-334.
13. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001;14:686-694.
14. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-689.
15. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, Nimer SD, Teruya-Feldstein J. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-974.
16. Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R, Pileri S, Dirnhofer S. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;16:1141-1147.
17. Zettl A, Meister S, Katzenberger T, Kalla J, Ott MM, Muller-Hermelink HK, Ott G. Immunohistochemical analysis of B-cell lymphoma using tissue microarrays identifies particular phenotypic profiles of B-cell lymphomas. Histopathology 2003;43:209-219.
18. Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B, Zinzani PL. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002;41:482-509.
19. Lossos IS, Levy R. Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol 2003;77:321-329.
20. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
21. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
22. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-9996.
23. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
24. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A, Perkins SL. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-470.
25. Ponzoni M, Ferreri AJ, Pruneri G, Pozzi B, Dell'Oro S, Pigni A, Pinotti G, Villa E, Freschi M, Viale G, Capella C. Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. Int J Cancer 2003;106:288-291.
26. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-1143.
27. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
28. de Leval L, Braaten KM, Ancukiewicz M, Kiggundu E, Delaney T, Mankin HJ, Harris NL. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 2003;27:1269-1277.
29. Woolson RF, Clarke WR. Statistical methods for the analysis of biomedical data. New York: John Wiley and Sons; 2002. pp 263-306.
30. De la Taille A, Viellefond A, Berger N, Boucher E, De Fromont M, Fondimare A, Molinie V, Piron D, Sibony M, et al. Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. Hum Pathol 2003;34:444-449.
31. Piris MA, Pezzella F, Martinez MJ, Orradre JL, Villuendas R, Sanchez BM, Cuena R, Cruz MA, Martinez B, Pezella F. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994;69:337-341.
32. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-609.
33. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, Pacini R, Alunni C, Natali-Tanci L, Ugolini B, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95: 2084-2092.
34. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
35. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
36. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
37. Kim SZ, Chow KU, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer SA, Harder L, Hoelzer D, Mitrou PS, Weidmann E. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 2004;45:2037-2045.